Acute myeloid leukemia dasatinib dosage

When patients with acute myeloid leukemia (AML) are treated with dasatinib (Dasatinib), the dosage regimen usually needs to be individually adjusted based on the patient's specific condition, age, weight, renal function, liver function and other factors. However, it should be noted that dasatinib is not a first-line standard treatment for AML, but may be considered in certain circumstances, such as AML with Philadelphia chromosome positivity (Ph+) or as a second-line treatment.

Regarding the dosage of dasatinib in AML, although there may be less detailed dosage guidance directly for AML, you can refer to its dosage regimen in similar hematological tumors (such as chronic myeloid leukemiaCML) and combine it with the judgment of clinicians.

For adult patients, dasatinib may be considered ifAML patients are Ph+ and have poor response or resistance to other treatments (such as chemotherapy).

The starting dose may be based on disease severity and patient tolerance, but does not usually directly mirror the dosage regimen of CML. In the absence of specific guidance, doctors may adjust doses based on clinical experience, possibly starting at a lower dose and gradually increasing to a dose that is tolerated and effective by the patient.

For pediatric patients, due to limited safety and efficacy data, dasatinib is generally not recommended for adolescents and children AML under the age of 18.

The dose of dasatinib must be individualized based on the patient's specific condition. During the treatment process, the patient's blood routine, liver and kidney function and other indicators, as well as the occurrence of adverse reactions, should be closely monitored, and the dose or treatment plan should be adjusted in a timely manner if necessary. Dasatinib may be given in combination with other medicines to enhance the effectiveness of treatment. At this time, special attention should be paid to drug-drug interactions and potential adverse reactions.